Boston’s biotech industry raised more than $1.5 billion in venture capital funding in May, BostInno reported.
Among the handful of startups to benefit from funding include Amwell, a Boston-based telemedicine company, that raised $194 million in Series C funding as some doctors treat patients by video messaging; Atea Pharmaceuticals, a Boston-based developer of therapies for viral diseases that raised $215 million in Series D funding; and Lowell startup Rapid Micro Biosystems, a provider of microbial detection technology, that received $120 million.
BostInno reported that fundraising for new investments by venture capital and private equity firms was less but still evident.
Cohere Capital Partners, a Boston-based private equity firm focused exclusively on middle-market growth companies, closed its initial fund at $200 million, and Founder Collective raised $85 million for its newest fund, BostInno reported.
Below are the startups that raised capital in May, according to data compiled by BostInno.
- LaunchPad Medical of Lowell received a $2.5 million Direct-to-Phase II Small Business Innovation Research grant from the National Institute of Neurological Disorders and Stroke to advance the development of Tetranite, its bone adhesive biomaterial technology.
- Boston-based Jellyfish, a startup behind an engineering management platform, raised more than $12 million in Series A funding from Accel and Wing Venture Capital.
- Digital Guardian, of Waltham, a data loss prevention software company, raised $35 million in equity, according to a Securities and Exchange Commission (SEC) filing.
- Ventus Therapeutics launched with $60 million from Versant Ventures and GV. The company, which has offices in Waltham and Montreal, said it plans to create drugs that target the immune system’s first line of defense.
- Cambridge-based agtech startup CiBO Technologies raised $10 million in equity, according to an SEC filing.
- XRHealth netted a $450,000 grant from the Israeli Innovation Authority to fight COVID-19.
- Waltham-based Viridian Therapeutics, a biopharmaceutical company focusing on natural chemical-free therapeutics, sold shares worth $2 million in a $5 million equity round.
- Day Zero Diagnostics, founded in 2016 at Pagliuca Harvard Life Lab, was awarded $6.2 million in funding from Boston-based Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator.